^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    keynatinib (TL007)

    i
    Other names: TL007, TL 007, TL-007, ML-007
    Associations

    News

    Trials
    Company:
    Logix Pharma, Medolution
    Drug class:
    EGFR inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    Keynatinib in Treated Patients With NSCLC and Brain Metastases (clinicaltrials.gov)
    P2, N=30, Recruiting, Medolution Ltd. | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    keynatinib (TL007)
    1year
    Phase Ib Clinical Study of Keynatinib (clinicaltrials.gov)
    P1, N=75, Recruiting, Medolution Ltd. | Trial completion date: Apr 2024 --> Apr 2028 | Trial primary completion date: Oct 2023 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    CCND1 (Cyclin D1)
    |
    CCND1 overexpression • CCND1 expression • CCND1-H
    |
    keynatinib (TL007)
    over2years
    Phase Ib Clinical Study of Keynatinib (clinicaltrials.gov)
    P1, N=75, Recruiting, Medolution Ltd. | Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Oct 2022 --> Oct 2023
    Trial completion date • Trial primary completion date
    |
    CCND1 (Cyclin D1)
    |
    CCND1 overexpression • CCND1 expression • CCND1-H
    |
    keynatinib (TL007)
    almost4years
    Phase Ib Clinical Study of Keynatinib (clinicaltrials.gov)
    P1, N=75, Recruiting, Medolution Ltd.
    Clinical • New P1 trial
    |
    CCND1 (Cyclin D1)
    |
    CCND1 overexpression • CCND1 expression • CCND1-H
    |
    keynatinib (TL007)